DF
MCID: DNG003
MIFTS: 69

Dengue Disease (DF)

Categories: Blood diseases, Genetic diseases, Infectious diseases, Liver diseases, Muscle diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 11 14 16
Dengue Fever 11 19 58 75 2 14 71
Dengue 53 41 43 33
Df 19 58 2
Dengue Virus Infection 19 58
Dengue Shock Syndrome 19 71
Dengue Haemorrhagic Fever Without Warning Signs 33
Dengue Haemorrhagic Fever with Warning Signs 33
Dengue Fever Without Warning Signs 33
Dengue Haemorrhagic Fever Grade 1 33
Southeast Asia Haemorrhagic Fever 33
Dengue Haemorrhagic Fever Grade 2 33
Dhf -[dengue Haemorrhagic Fever] 33
Dengue Fever with Warning Signs 33
Philippine Haemorrhagic Fever 33
Philippine Hemorrhagic Fever 19
Singapore Haemorrhagic Fever 33
Singapore Hemorrhagic Fever 19
Thailand Haemorrhagic Fever 33
Bangkok Haemorrhagic Fever 33
Dengue Hemorrhagic Fever 19
Thai Hemorrhagic Fever 19
Hemorrhagic Dengue 19
Classical Dengue 11
Breakbone Fever 11
Classic Dengue 11
Severe Dengue 71

Characteristics:


Prevelance:

Dengue Fever: >1/1000 (Worldwide) 1-9/1000000 (Europe, Belgium, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Portugal, Slovenia, Spain, United Kingdom) 1-9/100000 (Europe, Austria, Sweden, Norway) <1/1000000 (Croatia, Luxembourg, Slovakia, Greece) 58

Age Of Onset:

Dengue Fever: All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Dengue Disease

MedlinePlus: 41 Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found: Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows

MalaCards based summary: Dengue Disease, also known as dengue fever, is related to dengue shock syndrome and dengue hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Dengue Disease is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and endothelial, and related phenotypes are fever and headache

Disease Ontology: 11 A viral infectious disease that results in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

CDC: 2 Dengue viruses are spread to people through the bite of an infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito. Dengue is common in more than 100 countries around the world. Forty percent of the world's population, about 3 billion people, live in areas with a risk of dengue. Dengue is often a leading cause of illness in areas with risk.

GARD: 19 Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).

Orphanet: 58 Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome, or DSS).

Wikipedia: 75 Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Related Diseases for Dengue Disease

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 920)
# Related Disease Score Top Affiliating Genes
1 dengue shock syndrome 31.9 SULT1A3 SENP8 IVNS1ABP IL10 CLEC5A CD209
2 dengue hemorrhagic fever 31.7 SENP8 PTPN11 IVNS1ABP IL10 CLEC5A CD40LG
3 myelitis 31.0 IL10 IFNB1 CCR6
4 neuritis 30.9 IL10 CCL5 CCL4 CCL3
5 neutropenia 30.8 PTPN11 IL10 FCGR1A CD40LG
6 invasive aspergillosis 30.8 IL10 CD209 CCR6
7 kawasaki disease 30.8 FCGR1A CD40LG CCL5
8 plasmodium falciparum malaria 30.8 IL10 CCL5 CCL4 CCL3
9 covid-19 30.7 IL10 IFNB1 CCR6 CCL3
10 severe acute respiratory syndrome 30.7 IL7 IL10 IFNB1 CD209 CCL5 CCL3
11 crimean-congo hemorrhagic fever 30.7 PIK3C2A IL10 IFNB1
12 rubella 30.7 IL10 IFNB1 CD40LG
13 polyradiculoneuropathy 30.7 IL10 CCL5 CCL4
14 murray valley encephalitis 30.7 SENP8 CD209
15 hepatitis e 30.7 IL10 IFNB1 CD40LG
16 proteasome-associated autoinflammatory syndrome 1 30.6 IL10 CCL5 CCL3
17 respiratory syncytial virus infectious disease 30.6 IFNB1 CCL5 CCL3
18 aspergillosis 30.6 IL10 CD209 CCR6 CCL5 CCL3
19 hemophagocytic lymphohistiocytosis 30.6 IL7 IL10 CCR6 CCL5 CCL3
20 middle east respiratory syndrome 30.6 IFNB1 CCR6 CCL3
21 exanthem 30.5 PIK3C2A IL10 CCR6
22 myocarditis 30.5 PIK3C2A IL10 CD40LG CCL5 CCL3
23 acquired immunodeficiency syndrome 30.5 NEAT1 IL10 CD40LG CCL3
24 meningoencephalitis 30.4 IL10 CD40LG CCR6 CCL5
25 viral encephalitis 30.4 IL10 IFNB1 CCR6 CCL5
26 severe covid-19 30.4 IL7 IL10 IFNB1 CCR6 CCL3
27 bacterial sepsis 30.4 IL10 IFNB1 CCR6
28 endocarditis 30.3 PIK3C2A IL10 CCL4
29 human cytomegalovirus infection 30.3 IL10 IFNB1 CCR6
30 zika fever 30.3 IFNB1 CD209
31 allergic disease 30.3 IL10 CCR6 CCL5 CCL3
32 chickenpox 30.3 IL10 IFNB1 CCR6
33 anemia, autoimmune hemolytic 30.3 IL10 CD40LG CCR6
34 mumps 30.3 IL10 IFNB1 CD40LG
35 primary progressive multiple sclerosis 30.2 IL10 IFNB1 CCR6
36 thrombocytopenia 30.2 PTPN11 PIK3C2A IL7 IL10 IFNB1 FCGR1A
37 severe combined immunodeficiency 30.2 IL7 IL10 IFNB1 CD40LG CCR6
38 schistosomiasis 30.2 IL10 CD40LG CCL5 CCL3
39 lymphadenitis 30.2 IL10 CD209 CCR6
40 bronchiolitis 30.2 IL10 CCL5 CCL4 CCL3
41 toxoplasmosis 30.2 PIK3C2A IL10 CD40LG CCL3
42 meningitis 30.2 IL10 CCL5 CCL4 CCL3
43 respiratory failure 30.2 PIK3C2A IL7 IL10 IFNB1 CCR6 CCL5
44 retinal vasculitis 30.2 IVNS1ABP IFNB1 CCR6 CCL4
45 bacterial pneumonia 30.2 IL10 IFNB1 CCR6 CCL3
46 west nile fever 30.2 RNASEL IFNB1 CD209
47 pfeiffer syndrome 30.2 PTPN11 IL10 CD40LG CCR6
48 pneumonia 30.1 PIK3C2A IL10 CD40LG CCL5 CCL3
49 spinal cord disease 30.1 IL10 IFNB1 CCR6
50 hypertension, essential 30.1 SULT1A3 PIK3C2A MIR30E IL10 CD40LG CCR6

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

Human phenotypes related to Dengue Disease:

58 30 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001945
2 headache 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002315
3 abdominal pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0002027
4 arthralgia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002829
5 skin rash 58 30 Frequent (33%) Frequent (79-30%)
HP:0000988
6 pruritus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000989
7 nausea and vomiting 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002017
8 hypotension 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002615
9 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002240
10 ascites 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001541
11 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001873
12 gastrointestinal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002239
13 epistaxis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000421
14 gingival bleeding 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000225
15 petechiae 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000967
16 bruising susceptibility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000978
17 lethargy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001254
18 cerebral hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001342
19 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002014
20 leukopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001882
21 hypoproteinemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003075
22 cardiorespiratory arrest 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006543

UMLS symptoms related to Dengue Disease:


fever; pruritus

MGI Mouse Phenotypes related to Dengue Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.93 CCL3 CD209 CD40LG FCGR1A HCFC1 IL10
2 immune system MP:0005387 9.77 CCL3 CCL5 CCR6 CD209 CD40LG CLEC5A
3 hematopoietic system MP:0005397 9.44 CCL3 CCL5 CCR6 CD209 CD40LG FCGR1A

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6 774
3 Neurotransmitter Agents Phase 4
4 Anti-Allergic Agents Phase 4
5
Histamine phosphate Phase 4 51-74-1 134614
6 Histamine H1 Antagonists Phase 4
7 Histamine Antagonists Phase 4
8 Dermatologic Agents Phase 4
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
11
Montelukast Approved Phase 2, Phase 3 158966-92-8 5281040
12 Protective Agents Phase 3
13 Insect Repellents Phase 3
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
15 Leukotriene Antagonists Phase 2, Phase 3
16 Anti-Asthmatic Agents Phase 2, Phase 3
17 Hormones Phase 2, Phase 3
18 Hormone Antagonists Phase 2, Phase 3
19 Respiratory System Agents Phase 2, Phase 3
20
Hydrocortisone succinate Approved Phase 2 2203-97-6 3643
21
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
22
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 3640 5754
23
Ribavirin Approved Phase 2 36791-04-5 37542
24
Chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
25
Ivermectin Approved, Investigational, Vet_approved Phase 2 70288-86-7 9812710 6427057
26
Framycetin Approved, Experimental, Vet_approved Phase 2 1404-04-2, 119-04-0, 3947-65-7 413349 8378
27
Phenol Approved, Experimental Phase 2 108-95-2 996
28
Streptomycin Approved, Vet_approved Phase 2 57-92-1 19649
29
Metformin Approved Phase 1, Phase 2 1115-70-4, 657-24-9 4091
30
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 2 55-56-1 2713 9552079
31 Kava Approved, Investigational, Nutraceutical Phase 2 9000-38-8
32
Melatonin Approved, Nutraceutical, Vet_approved Phase 2 73-31-4 896
33 Antimetabolites Phase 2
34 Hydrocortisone 17-butyrate 21-propionate Phase 2
35 Amebicides Phase 1, Phase 2
36 Antiprotozoal Agents Phase 1, Phase 2
37 Antimalarials Phase 1, Phase 2
38 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
39 Vaccines Phase 2
40 Anti-Infective Agents Phase 2
41 Antiparasitic Agents Phase 2
42 Hemostatics Phase 2
43 Plasma-lyte 148 Phase 2
44 Hypoglycemic Agents Phase 1, Phase 2
45 Chlorhexidine gluconate Phase 2
46 Antirheumatic Agents Phase 2
47 Interleukin 1 Receptor Antagonist Protein Phase 2
48 Antiviral Agents Phase 2
49 Papaya Approved Phase 1
50
Aluminum sulfate Approved Phase 1 10043-01-3

Interventional clinical trials:

(show top 50) (show all 228)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Unknown status NCT04076254 Phase 3 Albumins;Fluid
3 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
5 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
6 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03771963 Phase 3
7 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
8 A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue Completed NCT04313244 Phase 3
9 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
10 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
11 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
12 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
13 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
14 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
15 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue Completed NCT03341637 Phase 3
16 A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue Completed NCT03525119 Phase 3
17 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
18 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
19 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3 Placebo
20 Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients: a Multicenter Randomized, Double-blind, Placebo Controlled, Superiority Trial Recruiting NCT04673422 Phase 2, Phase 3 Montelukast;Placebo
21 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Immunogenicity of the Dengue 1, 2, 3, 4 (Attenuated) Vaccine From Instituto Butantan Recruiting NCT02406729 Phase 3
22 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Active, not recruiting NCT03999996 Phase 3
23 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old Active, not recruiting NCT02747927 Phase 3 Placebo
24 Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Active, not recruiting NCT04343521 Phase 3
25 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Terminated NCT02992418 Phase 3
26 Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
27 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
28 Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults Unknown status NCT01696422 Phase 2
29 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
30 Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines Completed NCT02628444 Phase 2
31 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
32 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
33 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
34 A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America Completed NCT02302066 Phase 2
35 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
36 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
37 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
38 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
39 An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults Completed NCT03746015 Phase 2
40 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
41 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
42 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
43 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
44 A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore Completed NCT02425098 Phase 2
45 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
46 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
47 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
48 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
49 A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
50 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

Organs/tissues related to Dengue Disease:

MalaCards : Skin, Bone, Endothelial, Liver, T Cells, Monocytes, Kidney

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 26354)
# Title Authors PMID Year
1
Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects. 62 41
35939501 2022
2
Disruption of spatiotemporal clustering in dengue cases by wMel Wolbachia in Yogyakarta, Indonesia. 62 41
35701454 2022
3
Use of mobile data collection systems within large-scale epidemiological field trials: findings and lessons-learned from a vector control trial in Iquitos, Peru. 41
36243698 2022
4
Cardiac tamponade in a patient with dengue fever and lupus nephritis: a case report. 53 62
20089524 2010
5
Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor. 53 62
20108979 2010
6
Gene expression analysis during dengue virus infection in HepG2 cells reveals virus control of innate immune response. 53 62
19837110 2010
7
Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. 53 62
19822367 2009
8
Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection. 53 62
19923450 2009
9
Early diagnosis of dengue virus infection by detection of dengue viral antigen in peripheral blood mononuclear cell. 53 62
19755928 2009
10
Evaluation of dengue NS1 antigen detection tests with acute sera from patients infected with dengue virus in Venezuela. 53 62
19733994 2009
11
The relationship of interacting immunological components in dengue pathogenesis. 53 62
19941667 2009
12
Neurologic dengue manifestations associated with intrathecal specific immune response. 53 62
19858464 2009
13
Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. 53 62
19592650 2009
14
Super induction of dengue virus NS1 protein in E. coli. 53 62
19232392 2009
15
Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. 53 62
19264772 2009
16
Spatio-temporal tracking and phylodynamics of an urban dengue 3 outbreak in São Paulo, Brazil. 53 62
19478848 2009
17
Hanta virus infection during dengue virus infection outbreak in Indonesia. 53 62
19390126 2009
18
Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. 53 62
19264337 2009
19
Detection of dengue nonstructural 1 (NS1) protein in Vietnamese patients with fever. 53 62
19232866 2009
20
Patterns of dengue virus IgM and IgG antibodies in suspected cases of dengue in Jamaica, 2003-2006. 53 62
19478396 2009
21
Retrospective serological study on sequential dengue virus serotypes 1 to 4 epidemics in Tainan City, Taiwan, 1994 to 2000. 53 62
19122918 2008
22
Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. 53 62
18679379 2008
23
Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. 53 62
18685015 2008
24
Skin lesions in hospitalized cases of dengue Fever. 53 62
18940116 2008
25
DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. 53 62
18593570 2008
26
Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. 53 62
18788905 2008
27
Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. 53 62
18714359 2008
28
Identification of human hnRNP C1/C2 as a dengue virus NS1-interacting protein. 53 62
18471994 2008
29
Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. 53 62
18578883 2008
30
Use of a commercial enzyme immunoassay to monitor dengue virus replication in cultured cells. 53 62
18439289 2008
31
Treatment of yellow fever. 53 62
18061688 2008
32
Characterization of Asn130-to-Ala mutant of dengue type 1 virus NS1 protein. 53 62
18288598 2008
33
CD209 genetic polymorphism and tuberculosis disease. 53 62
18167547 2008
34
Evaluation of the Panbio dengue virus nonstructural 1 antigen detection and immunoglobulin M antibody enzyme-linked immunosorbent assays for the diagnosis of acute dengue infections in Laos. 53 62
17889487 2008
35
Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. 53 62
18279077 2008
36
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. 53 62
18052531 2007
37
Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. 53 62
17958746 2007
38
Prospective study to determine accuracy of rapid serological assays for diagnosis of acute dengue virus infection in Laos. 53 62
17715330 2007
39
Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. 53 62
17898184 2007
40
[Aminotransferases serum levels in patients with Dengue type 3]. 53 62
18180838 2007
41
Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES. 53 62
17416433 2007
42
Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. 53 62
16914345 2007
43
Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. 53 62
17329445 2007
44
Characterization of dengue virus serotype 1 in epidemics in Porto Velho, Rondônia, in 2001-2003. 53 62
17653458 2007
45
The distribution of DEN infected people in Dushan and Xingyi area of Yunnan-Guizhou Plateau, China. 53 62
17257502 2006
46
CD40 ligand enhances dengue viral infection of dendritic cells: a possible mechanism for T cell-mediated immunopathology. 53 62
17056582 2006
47
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 53 62
17006283 2006
48
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). 53 62
17005690 2006
49
Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+ T cells. 53 62
17005819 2006
50
Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. 53 62
16894199 2006

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon alpha inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase regulatory subunit M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55 Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 DLG associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC binding and spindle associated 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3 Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan mediated motility receptor Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog Blood + 3.80 0.000
21 CDK1 cyclin dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25 component of NDC80 kinetochore complex Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein family member 3 Blood - 3.72 0.000
27 TOP2A DNA topoisomerase II alpha Blood + 3.71 0.000
28 CCN3 cellular communication network factor 3 Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin dependent kinase inhibitor 3 Blood + 3.62 0.000
32 PCLAF PCNA clamp associated factor Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1 Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4 Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1 Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM assembly factor for spindle microtubules Blood + 3.52 0.000
42 OR2W3 olfactory receptor family 2 subfamily W member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 CCL3 CCL4 CCL5 CCR6 CD209 CD40LG
2
Show member pathways
13.5 IL7 IL10 IFNB1 CD40LG CCR6 CCL5
3
Show member pathways
13.28 CCL3 CCL4 CCL5 CCR6 CD40LG IL10
4
Show member pathways
13.04 PTPN11 IL7 IL10 CD40LG CCR6 CCL5
5
Show member pathways
12.73 RNASEL PTPN11 IL7 IL10 IFNB1 FCGR1A
6
Show member pathways
12.7 IFNB1 CD209 CCL5 CCL4 CCL3
7 12.44 RNASEL IL10 CD40LG CCL5
8
Show member pathways
12.4 RNASEL PTPN11 IFNB1 FCGR1A
9
Show member pathways
11.88 CCL3 CCL4 CCL5 CCR6
10 11.87 IL7 IL10 CD209
11 11.8 RNASEL IFNB1 CCL3
12 11.76 IL10 CCR6 CCL3
13
Show member pathways
11.62 PTPN11 PIK3C2A FCGR1A
14 11.6 IL10 IFNB1 CD209
15 11.57 NEAT1 IL10 CD40LG
16 11.53 IL7 IL10 CCR6 CCL3
17 11.51 CCL5 CCL4 CCL3
18 11.49 IL10 CCL4 CCL3
19 11.48 PIK3C2A IL10 CD40LG
20
Show member pathways
11.23 IL10 CCL4 CCL3
21 11.13 IL10 CCL5 CCL4 CCL3
22 11.07 IL7 IL10 IFNB1
23 11.01 CCL5 CCL4 CCL3
24 10.84 IL7 IL10 CD40LG CCL5 CCL4 CCL3
25 10.82 RNASEL IFNB1
26 10.73 IL10 IFNB1 CCL5 CCL4 CCL3

GO Terms for Dengue Disease

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 CCL3 CCL4 CCL5 CCR6 CD40LG CLEC5A
2 chemotaxis GO:0006935 10.08 CCR6 CCL5 CCL4 CCL3
3 response to virus GO:0009615 10.08 IVNS1ABP IFNB1 CCL5 CCL4
4 monocyte chemotaxis GO:0002548 10 CCL5 CCL4 CCL3
5 negative regulation of viral genome replication GO:0045071 9.99 RNASEL IFNB1 CCL5
6 chemokine-mediated signaling pathway GO:0070098 9.97 CCR6 CCL5 CCL4 CCL3
7 lymphocyte chemotaxis GO:0048247 9.93 CCL5 CCL4 CCL3
8 leukocyte cell-cell adhesion GO:0007159 9.91 CCL5 CD209 CD40LG
9 positive regulation of calcium ion transport GO:0051928 9.88 CCL5 CCL4 CCL3
10 eosinophil chemotaxis GO:0048245 9.8 CCL5 CCL4 CCL3
11 B cell proliferation GO:0042100 9.76 IL7 IL10 IFNB1 CD40LG
12 negative regulation by host of viral transcription GO:0043922 9.73 CCL3 CCL4 CCL5
13 immune response GO:0006955 9.7 IL7 IL10 FCGR1A CD40LG CCR6 CCL5
14 positive regulation of natural killer cell chemotaxis GO:2000503 9.1 CCL5 CCL4 CCL3

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.8 CCL5 CCL4 CCL3
2 CCR chemokine receptor binding GO:0048020 9.73 CCL5 CCL4 CCL3
3 CCR5 chemokine receptor binding GO:0031730 9.63 CCL5 CCL4 CCL3
4 CCR1 chemokine receptor binding GO:0031726 9.43 CCL5 CCL4 CCL3
5 cytokine activity GO:0005125 9.4 IL7 IL10 IFNB1 CD40LG CCL5 CCL4

Sources for Dengue Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....